Skip to content

Neurophysiological and Immunological Effects of the Transition From Combustible to Electronic Cigarettes

Neurophysiological and Immunological Effects of the Transition From Combustible to Electronic Cigarettes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02433015
Acronym
ECIG
Enrollment
27
Registered
2015-05-04
Start date
2015-01-31
Completion date
2016-09-24
Last updated
2017-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine Dependence, Tobacco Smoking

Keywords

Electronic Cigarette

Brief summary

The objective of this study is to examine the cognitive, immunological, and neurophysiological effects of transitioning from tobacco cigarettes to electronic cigarettes. The central hypothesis of this study is that this transition will be accompanied by a decrease in peripheral inflammation, which will lead to significant changes in the neurocircuitry underlying interoception and appetite.

Detailed description

Participants who are current cigarette smokers will be randomly assigned to either the experimental or control groups. Following a baseline psychiatric assessment session, subjects will return to the study center for two to three additional follow-up visits. During the second visit, all subjects will undergo a functional magnetic resonance imaging (fMRI) scanning session, during which they will perform a series of functional neuroimaging tasks designed to examine the neural substrates involved in visceral interoception and eating behavior. Prior to the start of the scan session, blood samples will be collected from each subject, for the measurement of bio-markers related to nicotine use and peripheral inflammation. After the end of the second visit, subjects within the experimental group will be asked to switch from combustible to electronic cigarettes. Subjects within the control group will continue to smoke combustible cigarettes as previously. During the third visit, which will follow two to eight weeks after the second visit, all subjects will provide a second blood sample and complete a second fMRI scan session. Both groups of participants will complete the same fMRI tasks as they did during the second visit.

Interventions

OTHERElectronic Cigarette

eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution

Smoke own brand of cigarette as previously

Sponsors

University of Oklahoma
CollaboratorOTHER
Laureate Institute for Brain Research, Inc.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* current cigarette smokers who have smoked for at least one year * right-handed adults * able to provide written informed consent

Exclusion criteria

* use of anticonvulsant, stimulant, or antipsychotic medication for 3 weeks prior to scanning * any medical conditions or medications likely to influence cerebral blood flow or neurological function including cardiovascular, respiratory, endocrine and neurological diseases * any history of drug (other than nicotine) or alcohol abuse within 1 year * current pregnancy or breast feeding * primary language other than English * meeting general MRI

Design outcomes

Primary

MeasureTime frameDescription
Change in overall levels of peripheral inflammatory cytokines2-8 weeksA composite measure of change in overall blood serum levels of multiple peripheral cytokines (CRP, TNF-alpha, sVCAM, IL-1RA, IL-6) between study visits two and three.

Secondary

MeasureTime frameDescription
Frequency of Electronic Cigarette use2-8 weeksDaily use of electronic cigarette between study visits two and three.
Change in exhaled Carbon Monoxide2-8 weeksChange in exhaled Carbon Monoxide between study visits two and three.
Frequency of Tobacco Cigarette use2-8 weeksAverage number of tobacco cigarettes smoked between study visits two and three.
Change in cotinine levels2-8 weeksChange in serum cotinine levels between study visits two and three.
Change in BOLD fMRI response during interoception2-8 weeksDifference in the brain's hemodynamic response during a task of interoceptive attention to visceral signals, measured by percent change of the BOLD fMRI signal, between study visits two and three.
Change in BOLD fMRI response to food pictures2-8 weeksDifference in the brain's hemodynamic response to viewing pictures of appetizing food, measured by percent change of the BOLD fMRI signal, between study visits two and three.
Change in Blood Oxygen Level-Dependent (BOLD) resting state functional connectivity during fMRI2-8 weeksDifference in resting-state functional connectivity between brain regions, measured by z-scores of correlated spontaneous fluctuations of the BOLD fMRI signal, between study visits two and three.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026